Development and Novel Therapeutics in Diabetic Retinopathy

Area of Science:

• Ophthalmology
• Endocrinology
• Pharmacology

Background:

• Diabetic retinopathy (DR) is a significant complication of diabetes mellitus, leading to progressive retinal damage and potential vision impairment.
• The increasing global prevalence of DR necessitates advancements in treatment optimization and the development of novel therapeutic strategies.
• Current management includes anti-vascular endothelial growth factor (anti-VEGF) and corticosteroid therapies, but challenges remain.

Purpose of the Study:

• To review the epidemiological trends of diabetic retinopathy.
• To summarize current and emerging therapeutic interventions for DR, including pharmacological and technological advancements.
• To explore challenges in DR treatment development and the potential role of artificial intelligence (AI) in its management.

Main Methods:

• Literature review of epidemiological data on DR prevalence.
• Analysis of current pharmacological treatments (anti-VEGF, corticosteroids) and novel drug therapies in clinical trials.
• Exploration of modern treatments like laser therapy and the integration of AI in DR screening and management.

Main Results:

• DR prevalence is increasing, highlighting the need for improved treatments.
• Several pharmacological therapies are effective in reducing vision impairment risk.
• Novel drug therapies and AI applications show promise for enhanced DR diagnosis and management.

Conclusions:

• Optimizing existing treatments and developing new drugs are essential for managing DR.
• Addressing challenges like healthcare costs and improving mechanistic understanding is critical.
• AI integration offers significant potential for early diagnosis and improved patient care in DR management.